Quantcast

Latest Corinne Goldsmith Dickinson Center for Multiple Sclerosis Stories

2009-04-15 08:46:00

Only 39 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed neurologists anticipate that less than 30 percent of their use of emerging oral agents --- Merck Serono's oral cladribine, Novartis/Mitsubishi Pharma's...

2009-02-18 14:46:00

Aurora St. Luke's Medical Center Discovers Way to Fight Rare, but Deadly, Side Effect from Drug. MILWAUKEE, Feb. 18 /PRNewswire/ -- Researchers at Aurora St. Luke's Medical Center have developed a technique that counteracts an unusual, but serious, side effect from natalizumab (Tysabri(R)), a drug that fights multiple sclerosis (MS). The side effect is a brain virus called progressive multifocal leukoencephalopathy (PML). "This virus looks like a multiple sclerosis relapse," Dr. Bhupendra...

2009-02-04 07:00:00

Tysabri is Decision Resources' Gold Standard Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an oral disease-modifying therapy for relapsing-remitting multiple sclerosis would earn a 50 percent patient share in Europe and a 40 percent patient share in the United States,...

2009-01-29 17:30:00

U.S. medical scientists say they have used stem cell therapy to apparently reverse the neurological dysfunctions caused by early-stage multiple sclerosis. Researchers from Northwestern University's Feinberg School of Medicine said they transplanted early-stage multiple sclerosis patients' own immune stem cells into the patients' bodies, thereby resetting their immune systems. This is the first time we have turned the tide on this disease, said Dr. Richard Burt, who led the study at...

2008-09-20 09:00:14

Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced additional data from its second Phase 3 clinical trial of Fampridine-SR (MS-F204) on walking ability in people with multiple sclerosis (MS) at the late breaking news session of the World Congress on Treatment and Research in Multiple Sclerosis, being held in Montreal, Canada. Previously, the Company announced the trial met its primary endpoint with a significantly greater proportion of people taking Fampridine-SR having a consistent...

2008-09-19 15:00:54

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS) and diabetes, today announced top-line data from the company's Phase IIb TERMS (Tovaxin(R) for Early Relapsing Multiple Sclerosis) study. Top-line results from the study demonstrated a positive trend in the reduction in annualized relapse rate (ARR) for patients treated with Tovaxin as compared to...

2008-09-19 15:00:12

New data from PreCISe, in clinically isolated syndrome patients, have demonstrated that COPAXONE(R) (glatiramer acetate injection) significantly improved neuro-axonal integrity in patients presenting with a first clinical event suggestive of multiple sclerosis (MS) versus patients who received placebo (p=0.03), as measured by proton magnetic resonance spectroscopy (MRS). This effect was maintained over two years of treatment. The data represent the first evidence of neuro-axonal...

2008-09-19 12:00:35

Teva Pharmaceutical Industries has announced new positive data from the longest prospective study of treatment to relapsing-remitting multiple sclerosis, which proves robust efficacy and safety of Copaxone. Findings demonstrated that more than 80% of patients were able to walk unassisted following 15 years of treatment and average disease duration of 22 years. The majority of the 100 patients in the study experienced either stable or improved disability rates over the duration of the...

2008-08-01 06:00:46

Peptimmune has received a US patent which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases. Peptimmune's PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the company plans to initiate its Phase II study in relapsing remitting...

2008-07-16 12:01:29

CAMBRIDGE, Mass., July 16 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced that it has completed a second close of $8.9 million of its Series D preferred stock offering with its investor syndicate led by New Enterprise Associates, MPM Capital, Hunt Ventures L.P., Boston Medical Investors and Silicon Valley Bank Capital, and its Chairman of the Board. The proceeds of the financing are primarily being used to advance clinical development of Peptimmune's...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related